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Background: The antidiabetic effects of the gut hormone xenin include augmenting insulin secretion and positively affecting pancreatic islet architecture. 
Methods: The current study has further probed pancreatic effects through sub-chronic administration of the long-acting xenin analogue, xenin-25[Lys13PAL], in both high fat fed (HFF) and streptozotocin (STZ)-induced insulin-deficient Ins1Cre/+;Rosa26-eYFP transgenic mice. Parallel effects on metabolic control and pancreatic islet morphology, including islet beta-cell lineage tracing were also assessed. 
Results: Xenin-25[Lys13PAL] treatment reversed body weight loss induced by STZ, increased plasma insulin and decreased blood glucose levels. There were less obvious effects on these parameters in HFF mice, but all xenin-25[Lys13PAL] treated mice exhibited decreased pancreatic alpha-cell areas and circulating glucagon. Xenin-25[Lys13PAL] treatment fully, or partially, returned overall islet and beta-cell areas in STZ- and HFF mice to those of lean control animals, respectively, and was consistently associated with decreased beta-cell apoptosis. Interestingly, xenin-25[Lys13PAL] also increased beta-cell proliferation and decreased alpha-cell apoptosis in STZ mice, with reduced alpha-cell growth noted in HFF mice. Lineage tracing studies revealed that xenin-25[Lys13PAL] reduced the number of insulin positive pancreatic islet cells that lost their beta-cell identity, in keeping with a decreased transition of insulin positive to glucagon positive cells. These beneficial effects on islet cell differentiation were linked to maintained expression of Pdx1 within beta-cells. Xenin-25[Lys13PAL] treatment was also associated with increased numbers of smaller sized islets in both models. 
Conclusion: Benefits of xenin-25[Lys13PAL] on diabetes includes positive modulation of islet cell differentiation, in addition to promoting beta-cell growth and survival.
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Introduction
Xenin is typically characterised as a 25 amino acid peptide hormone secreted from a subset of enteroendocrine K cells in response to food ingestion [1]. As such, xenin is released into the bloodstream, together with the K-cell derived incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), and intriguingly is known to potentiate the biological actions of GIP [2-5]. This is of particular significance in terms of a therapeutic drug target for type 2 diabetes mellitus (T2DM), since the insulin releasing effect of GIP is known to be compromised in T2DM [6]. Further studies reveal that xenin functions as an independent insulin secretagogue [4,7,8] and suppresses appetite [2]. The latter action is presumably related to a combination of inhibition of gastric emptying in addition to direct effects on hypothalamic neuronal circuits that control energy balance [9].
	As well being synthesised in the gut, early studies were able to extract and isolate the xenin precursor, proxenin, as well as the native peptide, from canine pancreatic tissue [10,11]. More recent immunohistochemical based methods reveal xenin expression in both pancreatic alpha- and beta-cells, with glucose and arginine acting as stimuli for islet xenin secretion, highlighting a potential paracrine/autocrine role for xenin in islet function [12]. In keeping with this, xenin co-localisation in beta-cells is decreased under situations of streptozotocin (STZ)-induced insulin deficiency and beta-cell loss, but increased by hydrocortisone-induced beta-cell expansion [12]. Furthermore, mechanistic in vitro studies have shown xenin to augment rodent and human beta-cell proliferation and protect these cells from cytokine-induced apoptosis [12]. Taken together, it is clear that xenin possesses a biological action profile with particularly exciting therapeutic promise for diabetes [13].   
	The biological half-life of xenin is short [4,5], precluding use of the native hormone as a potential therapeutic agent. To circumvent this issue, a number of long-acting, enzyme resistant, xenin analogues have been synthesised and characterised [7,8]. Notably, sustained twice-daily administration of these stabilised xenin peptides resulted in numerous metabolic benefits in high fat fed (HFF) mice, in addition to decreased pancreatic alpha-cell and increased beta-cell areas [7,8]. This confirms that long-acting xenin analogues, such as xenin-25[Lys13PAL], retain direct beneficial pancreatic islet actions in diabetes. Given that xenin peptides influence both alpha- and beta-cell mass, alongside a role for xenin in the maintenance of overall islet architecture [12], this might indicate that xenin is impactful in the well renowned processes of islet endocrine cell differentiation [14-17]. Indeed, lineage tracing studies reveal that pancreatic endocrine cell plasticity is highly relevant to diabetes, including dedifferentiation of mature insulin secreting beta-cells towards non-beta like endocrine cells in rodent and non-rodent models, as well as humans [18-23]. 




Xenin-25[Lys13PAL] was sourced from GL Biochem Ltd. (Shanghai, China) at greater than 95% purity.  Confirmation of peptide purity and identity were verified in-house using RP-HPLC and MALDI-TOF MS, as detailed previously [27].
Animals
All studies were conducted in 15 week old Ins1Cre/+;Rosa26-eYFP transgenic mice [25]. Mice were bred in-house by crossing homozygous Rosa26-eYFP mice and Ins1Cre/+ mice derived (both models on C57BL/6 background were purchased from Jackson Laboratory, Maine, USA). Presence of the Cre and ROSA26eYFP transgenes was confirmed by PCR genotyping, as previously described [24]. To provoke insulin-deficient diabetes, multiple low dose STZ (50 mg/kg body weight, i.p. in 0.1 M sodium citrate buffer, pH 4.5) or saline vehicle (0.9% w/v NaCl, i.p.) was injected daily (13:00 h, n=6, fasted for 4 h) over a period of 5 days [28]. To induce insulin-resistance and glucose intolerance, mice were allowed free access to high fat diet (45% fat, 20% protein, and 35% carbohydrate, Special Diet Services, Essex, U.K.) from weaning (4 weeks old) onwards. All other mice were maintained on standard rodent diet (10% fat, 30% protein and 60% carbohydrate; Trouw Nutrition, Northwich, UK) throughout. Animals were housed individually in an air-conditioned room at 22±2°C with 12 hours light and dark cycle with ad libitum access to respective diets and drinking water. All in vivo experiments were approved by Ulster University Animal Ethics Review Committee and conducted in accordance to the UK Animals (Scientific Procedures) Act 1986.

Experimental design
Following recruitment in respective studies, STZ and high fat fed (HFF) mice (n=6) received once daily injections (17:00 h) of saline vehicle (0.9% (w/v) NaCl) or xenin-25[Lys13PAL] (25 nmol/kg bw) for 10 or 12 days, respectively. The dose of xenin-25[Lys13PAL] was selected based on previous studies with this peptide in diabetic rodents [7]. Body weight, cumulative energy intake and circulating glucose levels were assessed at regular intervals. At the end of treatment, non-fasting blood glucose, plasma insulin and glucagon concentrations were determined. At termination, pancreatic tissues were excised, divided longitudinally so that each extract contained equivalent head and tail portions, and processed for immunohistochemistry or determination of insulin and glucagon content following acid-ethanol hormone extraction as previously described [28], or fixed in 4% PFA for 48 h at 4°C.

Immunohistochemistry 
Fixed tissues were sectioned (5 µm) and processed for antibody staining as described previously [28]. Every tenth section were selected from each pancreas (n=6) in a blinded manner, with approximately 80-100 islets analysed per treatment group. Slides were incubated with respective primary antibodies overnight at 4°C, and then appropriate fluorescent secondary antibodies. To stain nuclei, a final incubation was carried out at 37°C with 300 nM DAPI (Sigma-Aldrich, D9542). In addition, co-staining of insulin (1:500; Abcam, ab6995) or glucagon (PCA2/4, 1:200; raised in-house) with Ki-67 (1:400; Abcam ab15580) or TUNEL reaction mixture (Roche Diagnostics Ltd, UK) was used to assess beta-cell proliferation or apoptosis, respectively. To investigate beta cell lineage, co-staining of insulin or glucagon, as above, with GFP (1:1000; Abcam, ab5450) was employed. In addition, Pdx1 (1:200, Abcam, ab47308) co-expression in insulin positive cells was also evaluated. Following this, slides were rinsed in PBS and incubated for 45 minutes at 37°C with appropriate secondary antibodies including, Alexa Fluor594 goat anti-mouse IgG, Alexa Fluor488 goat anti-mouse IgG, Alexa Fluor594 goat anti-guinea pig IgG, Alexa Fluor488 goat anti-guinea pig IgG, Alexa Fluor594 goat anti-rabbit IgG, Alexa Fluor488 goat anti-rabbit IgG or Alexa Fluor488 donkey anti-goat IgG. Slides were finally incubated with DAPI for 15 mins at 37°C, and then mounted. Imaging was carried out using an Olympus fluorescent microscope (Olympus system microscope, model BX51) fitted with DAPI (350 nm) FITC (488 nm) and TRITC (594 nm) filters and a DP70 camera adapter system. CellF imaging software was used to assess islet area, beta-cell area, alpha-cell area, and islet size distribution [28]. ImageJ software was employed to evaluate beta- and alpha-cell proliferation and apoptosis, as well as Pdx1 co-expression with insulin positive cells. All counts were determined in a blinded manner with >60 islets analysed per treatment group.

Biochemical analyses 
Blood samples were collected from the cut tip on the tail vein, of conscious mice, at times indicated in Figure 2. Blood glucose was measured immediately using a hand-held Ascencia Contour blood glucose meter (Bayer Healthcare, Newbury, Berkshire, UK). For plasma insulin and glucagon, blood was collected in chilled fluoride/heparin coated micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) and centrifuged using a Beckman micro-centrifuge (Beckman Instruments, Galway, Ireland) for 10 minutes at 12,000 rpm. Plasma was extracted and stored at -20oC, until analysis. Plasma and pancreatic insulin and glucagon concentrations where subsequently assessed by an in-house radioimmunoassay [29] or commercially available ELISA kit (EZGLU-30K, Merck Millipore), respectively. 

Statistical analysis 
Statistical analyses were performed using GraphPad PRISM software (Version 5.0). Values are expressed as mean ± S.E.M. Comparative analyses between groups were carried out using a One- or Two-way ANOVA with Bonferroni’s post hoc test, as appropriate. The difference between groups was considered significant if p < 0.05.

Results
Effects of xenin-25[Lys13PAL] on body weight, cumulative energy intake, non-fasting glucose, insulin and glucagon in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice
Once daily administration of xenin-25[Lys13PAL] to HFF Ins1Cre/+;Rosa26-eYFP mice had no impact on percentage body weight change over a 12-day the treatment period (Figure 1A). Actual body weights of saline and xenin-25[Lys13PAL] treated HFF mice on day 0 were 35.3 ± 1.1 and 34.7 ± 0.9 g, whilst on day 12 these were 34.6 ± 1.4 and 33.9 ± 0.6 g, respectively, with lean control mice weighing 25.8 ± 0.2 and 25.6 ± 0.2 g on day 0 and 12, respectively. However, xenin-25[Lys13PAL] treatment for 10 days significantly (p < 0.001) countered the loss of body weight induced by multiple low dose STZ administration (Figure 1A). The xenin-25[Lys13PAL] treatment regimens had no effect of energy intake in either mouse model (Figure 1B). Circulating blood glucose levels were not elevated in HFF mice, but were significantly increased by STZ injection (Figure 2A,B). STZ-induced increases in blood glucose were significantly (p < 0.05) restrained by daily xenin-25[Lys13PAL] injection (Figure 2A,B). In keeping with this, non-fasting plasma insulin was elevated (p < 0.05) in xenin-25[Lys13PAL] STZ mice, and not significantly different when compared to lean controls (Figure 2C). Related circulating plasma insulin concentrations in saline (p < 0.05) and xenin-25[Lys13PAL] (p < 0.01) treated HFF mice were elevated (p < 0.01 and p < 0.001; respectively) when compared to lean controls (Figure 2C). Plasma glucagon concentrations were significantly reduced by xenin-25[Lys13PAL] in both STZ (p < 0.001) and HFF (p < 0.01) Ins1Cre/+;Rosa26-eYFP mice compared to respective saline controls, and not significantly different from lean control mice (Figure 2D). Pancreatic insulin content was reduced (p < 0.05 – p < 0.001), and glucagon content increased (p < 0.01), in all STZ mice (Figure 2E,F). In HFF mice, pancreatic insulin concentrations were significantly (p < 0.001) increased by xenin-25[Lys13PAL] treatment when compared to saline treated HFF and lean control mice (Figure 2E). Interestingly, pancreatic glucagon was decreased (p < 0.05) by high fat feeding, but returned to lean control levels by once daily xenin-25[Lys13PAL] injection (Figure 2F).

Effects of xenin-25[Lys13PAL] on pancreatic morphology in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice
Representative images of pancreatic tissue form xenin-25[Lys13PAL] treated STZ and HFF Ins1Cre/+;Rosa26-eYFP mice stained fluorescently for insulin, glucagon and DAPI are shown in Figure 3A. As would be predicted from these images, total pancreatic islet area was increased (p < 0.001) in saline treated HFF mice and decreased (p < 0.05) in STZ mice, when compared to lean controls (Figure 3B). Once daily xenin-25[Lys13PAL] treatment had several notable impacts on pancreatic architecture in these mice, and most importantly was largely associated with normalisation of pancreatic morphology in both models. As such, xenin-25[Lys13PAL] increased (p < 0.05) islet- and beta-cell areas in STZ mice, but decreased (p < 0.05) both of these parameters in HFF mice (Figure 3B,C). In the two Ins1Cre/+;Rosa26-eYFP mouse models, xenin-25[Lys13PAL] significantly (p < 0.01) decreased alpha-cell areas (Figure 3D). Interestingly, despite changes in islet-, beta- and alpha-cells areas induced by xenin-25[Lys13PAL] treatment in HFF mice (Figure 3B-D), the overall percentage of islet beta- and alpha-cells remained constant in these mice (Figure 3E,F). In STZ mice, xenin-25[Lys13PAL] increased (p < 0.05) the percentage of islet beta-cells (Figure 3E), and decreased (p < 0.01) the percentage of islet alpha-cells (Figure 3F). Xenin-25[Lys13PAL] consistently increased (p < 0.05) the percentage of smaller sized islets in all Ins1Cre/+;Rosa26-eYFP mice, at the expense of medium and larger sized islets (Figure 3G). 

Effects of xenin-25[Lys13PAL] on pancreatic alpha- and beta-cell proliferation and apoptosis in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice
Beta-cell apoptosis was increased in saline treated STZ (p < 0.001) and HFF (p < 0.05) Ins1Cre/+;Rosa26-eYFP mice, but normalised (p < 0.001) to lean control levels by once daily xenin-25[Lys13PAL] treatment (Figure 4A). Similarly, both mouse models presented with increased (p < 0.001) alpha cell apoptosis, which was fully (p < 0.05) or partially reversed by xenin-25[Lys13PAL] treatment (Figure 4B). Representative images of islets co-stained with TUNEL reagent and insulin (Figure 4C) or glucagon (Figure 4D) from each treatment group are also shown. In terms of islet cell proliferation, xenin-25[Lys13PAL] substantially (p < 0.01) increased beta-cell growth in STZ mice, but had no real influence on alpha-cell proliferation (Figure 5A,B). Pancreatic beta-cell proliferation was augmented (p < 0.01) by high fat feeding in Ins1Cre/+;Rosa26-eYFP mice, and xenin-25[Lys13PAL] treatment maintained this beta-cell proliferative effect (Figure 5A). HFF mice also presented with increased (p < 0.001) alpha-cell proliferation, but this was fully normalised (p < 0.01) by once daily xenin-25[Lys13PAL] administration (Figure 5B). Representative images of islets co-stained with Ki-67 and insulin (Figure 5C) or glucagon (Figure 5D) are shown.

Effects of xenin-25[Lys13PAL] on islet cell lineage in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice
Pancreatic endocrine cell lineage was investigated in Ins1Cre/+;Rosa26-eYFP mice by co-staining islet sections with insulin or glucagon and GFP, as depicted in Figure 6A&B. Notably, induction of diabetes by either multiple low dose STZ injection, or sustained high fat feeding, significantly (p < 0.001) increased the number of GFP positive/insulin negative cells (Figure 6C) and GFP positive/glucagon positive cells (Figure 6D). In HFF mice, treatment with xenin-25[Lys13PAL] returned the islet expression of these factors to lean control levels (Figure 6C,D). Xenin-25[Lys13PAL] also reversed (p < 0.001) the negative effect of STZ on the expression of GFP positive/insulin negative cells and GFP positive/glucagon positive islet cells, but levels were still elevated (p < 0.001) when compared to lean controls (Figure 6C,D). Notably, Pdx1 expression in insulin positive cells was decreased (p < 0.001) in both models, but significantly (p < 0.01 to p < 0.001) increased by once daily treatment with xenin-25[Lys13PAL] (Figure 6E). Representative images of islets co-stained with Pdx1 and insulin are shown for each treatment group (Figure 6F).

Discussion
Xenin-25[Lys13PAL] induced notable benefits on metabolism in both STZ and HFF Ins1Cre/+;Rosa26-eYFP mice, similar to previous observations with sustained upregulation of xenin signalling pathways in diabetic rodents [7,8,26]. Notably, body weight loss induced by multiple low dose STZ administration was fully rescued by xenin-25[Lys13PAL] treatment, despite lack of obvious effect on energy intake. Given that xenin-25[Lys13PAL] has previously been shown not to alter metabolic rate or energy expenditure in rodents when administered peripherally at the same dose [7], this benefit is likely due to direct recovery of STZ-induced pancreatic islet damage and resulting improved overall metabolic state [30]. Given that the onset of hyperglycaemia was delayed rather than prevented by xenin-25[Lys13PAL] in STZ mice, it is likely that beta-cell protection, as opposed to proliferation, was of greater importance [12]. Indeed, circulating insulin concentrations were returned to normal levels in xenin-25[Lys13PAL] treated STZ mice, with elevated plasma and pancreatic insulin also being a distinct feature of xenin-25[Lys13PAL] treatment in HFF mice. 
	In relation to this, hyperglucagonaemia which is a characteristic feature of human T2DM [31], was observed in STZ and HFF mice, alongside alpha-cell expansion [32-34]. Studies in both rodents and humans have shown that annulling glucagon receptor (GCGR) signalling is a highly effective therapeutic strategy in diabetes [35-40]. Interestingly, in the acute in vitro and in vivo setting, xenin has been shown to induce glucagon secretion [41,42]. However, in the current study, long-term treatment with xenin-25[Lys13PAL] evoked substantial reductions in circulating glucagon and pancreatic alpha-cell area in both STZ and HFF mice, suggesting secretory adaptations in the face of prolonged receptor activation. In addition, GIP exerts glucose-dependent effects on glucagon secretion [43] and investigation of potentiation of this action by xenin-25[Lys13PAL], as observed for GIP-induced insulin secretion [44], would be interesting. 
To further investigate changes in alpha-cells, pancreatic islet architecture and expression of key cell lineage markers were examined in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice [24,25]. In general, xenin-25[Lys13PAL] treatment was associated with a reversal of the detrimental islet effects observed in both rodent models, in line with improved metabolic phenotype. Thus, xenin-25[Lys13PAL] increased islet and beta-cell area in STZ mice, but decreased these parameters in HFF mice. Importantly, xenin-25[Lys13PAL] treatment was consistently associated with marked reductions in beta-cell apoptosis, which is of particular relevance given that all major forms of diabetes are linked to beta-cell loss [45,46]. This is also in full agreement with established beta-cell protective effects of activation of xenin cell signalling pathways [12]. As well as decreasing beta-cell apoptosis, augmentation of proliferation, or prevention of dedifferentiation and subsequent loss of function of adult beta-cells, represent an attractive strategy to address the beta-cell deficit in diabetes [18]. Although less evident under high fat feeding, xenin-25[Lys13PAL] induced a substantial increase of beta-cell growth in STZ mice, as assessed by Ki-67 staining. The acute islet stress induced by multiple STZ injection is a likely contributing factor to the different observations from HFF mice. In addition, any beta-cells that arrested in G1 phase of the cell cycle, prior to mitosis and cell division occurring, would still be assessed as Ki-67 positive proliferating beta-cells. Nonetheless, even relatively small increases of functional beta-cell mass can induce a physiologically relevant benefit on overall metabolism [47]. In addition, xenin is known to potentiate the biological activity of GIP [2,4,5], with both hormones secreted locally from pancreatic islets [12,48]. This could also have a beneficial influence on pancreatic architecture given the established positive effects of GIP on beta-cell growth and survival [49-51]. However, it should also be noted that actual proliferation rates of adult pancreatic beta-cells are low [52]. Indeed, corresponding observations on positive beta-cell growth effects of approved glucagon-like peptide-1 mimetics in animal models of diabetes, are only evidenced in human islets in vitro to date [53]. Nonetheless, beta-cell regeneration can also occur through promotion of alpha- to beta-cell transdifferentiation [54]. Thus, investigation of xenin-25[Lys13PAL] effects in transgenic rodent models with engineered alpha-cell lineage tracing technology are very interesting [55], especially given that xenin exerted such notable effects on alpha-cell area and glucagon secretion in the current setting. 
Further to the above, prevention of beta-cell dedifferentiation and subsequent transdifferentiation, known to be contributing factors to beta-cell loss [18,19,22,25,56], would also be advantageous in diabetes. Since alpha- and beta-cells share remarkably similar transcriptomes, it is postulated that aberrant islet cell differentiation is relevant in the aetiology of diabetes [57]. In the current setting, we unequivocally show that xenin-25[Lys13PAL] substantially reduces the loss of beta-cell identity provoked in HFF and STZ mice, as well as preventing conversion of mature beta-cells to glucagon positive endocrine cells. Triple staining of GFP, glucagon and insulin would have been useful to provide additional insight on islet cell lineage processes, and especially the relative impact to changes in alpha- and beta-cell areas, but was not possible due to methodological constraints. In addition, xenin-25[Lys13PAL] augmented Pdx1 expression within insulin positive islet cells, where Pdx1 is regarded as the master regulator of beta-cell phenotype and suppresses alpha-cell identity [58]. As such, loss of beta-cell Pdx1 is associated with impaired cell identity, and emergence of alpha-cell like features [21,59]. Taken together, these beneficial islet effects induced by xenin-25[Lys13PAL] would undoubtedly result in preserved beta-cell mass and function, as evidenced in both models. 
Although the true physiological role of xenin is only slowly being recognised [13] the xenin sequence, similar to insulin, is highly conserved during evolution [60], signifying important biological significance. We propose that one of the chief functions of xenin, produced locally within islets, may be related to conservation and protection of pancreatic islet structure and beta-cell mass. The current data support positive effects of xenin to preserve islet beta-cell mass through increased beta-cell proliferation and decreased apoptosis, as well as reduced beta-cell dedifferentiation, with obvious encouraging implications for the treatment of diabetes [13]. In this regard, protective effects against islet cell apoptosis may be underestimated, since this cellular process is associated with cytoplasmic contraction [61], making immunohistochemical hormone co-localisation staining somewhat challenging. Thus, it is possible that only those cells in the early stages of apoptosis where identified. The appearance of more smaller sized islets within the pancreatic tissues of both mouse models following xenin-25[Lys13PAL] treatment might also support a view of increased pancreatic islet neogenesis. Whilst further studies are clearly required, it is of interest to note that xenin regulates pancreatic exocrine cell function [1]. 
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Figure 1. Effects of xenin-25[Lys13PAL] on (A) body weight and (B) energy intake in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice. (A) Percentage body weight change was measured in STZ and HFF mice after once daily treatment with saline vehicle or xenin-25[Lys13PAL] (25 nmol/kg bw) for 10 or 12 days, respectively. (B) Energy intake was daily over the observation period. Values represent mean ± SEM for 6 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to lean controls. ∆∆∆p < 0.001 compared to respective STZ or HFF saline controls.

Figure 2. Effects of xenin-25[Lys13PAL] on circulating glucose, insulin and glucagon as well as pancreatic insulin and glucagon content in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice. (A) Blood glucose was assessed for 3 days prior to, and 10 or 12 days during, as appropriate, once daily treatment with saline vehicle or xenin-25[Lys13PAL] (25 nmol/kg bw). (B-F) Final circulating (B) blood glucose, (C) plasma insulin and (D) plasma glucagon concentrations, as well as pancreatic (E) insulin and (F) glucagon content. Values represent mean ± SEM for 6 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to lean controls. ∆p < 0.05, ∆∆p < 0.01 and ∆∆∆p < 0.001 compared to respective STZ or HFF saline controls.

Figure 3. Effects of xenin-25[Lys13PAL] on pancreatic morphology in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice. (A-G) Parameters were assessed in STZ and HFF mice after 10 or 12 days, respectively, once daily treatment with saline vehicle or xenin-25[Lys13PAL] (25 nmol/kg bw). (A) Representative images (40X) of islets showing insulin (red), glucagon (green) and DAPI (blue) immunoreactivity from each group of mice. (B) Islet, (C) beta and (D) alpha cell areas, percentage of islet (E) beta and (F) alpha cells and (G) islet size distribution were measured using CellF image analysis software. Values are mean ± SEM for 6 mice. **p < 0.01 and ***p < 0.001 compared to lean controls. ∆p < 0.05, ∆∆p < 0.01 and ∆∆∆p < 0.001 compared to respective STZ or HFF saline controls. ND – not detected. 

Figure 4. Effects of xenin-25[Lys13PAL] on pancreatic beta- and alpha-cell apoptosis in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice. (A,B) Parameters were assessed in STZ and HFF mice after 10 or 12 days, respectively, once daily treatment with saline vehicle or xenin-25[Lys13PAL] (25 nmol/kg bw). Pancreatic (A) beta and (B) alpha cell apoptosis were measured using TUNEL staining and quantified with ImageJ software. (C,D) Representative images (40X) of islets showing insulin or glucagon (both red) and TUNEL (green) immunoreactivity from each group of mice. Values are mean ± SEM for 6 mice. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to lean controls. ∆p < 0.05 and ∆∆∆p < 0.001 compared to respective STZ or HFF saline controls.

Figure 5. Effects of xenin-25[Lys13PAL] on pancreatic beta- and alpha-cell proliferation in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice. (A,B) Parameters were assessed in STZ and HFF mice after 10 or 12 days, respectively, once daily treatment with saline vehicle or xenin-25[Lys13PAL] (25 nmol/kg bw). Pancreatic (A) beta and (B) alpha cell proliferation were measured using Ki-67 staining and quantified with ImageJ software. (C,D) Representative images (40X) of islets showing insulin or glucagon (both green), Ki-67 (red) and DAPI (blue) immunoreactivity from each group of mice. Values are mean ± SEM for 6 mice. **p < 0.01 and ***p < 0.001 compared to lean controls. ∆∆p < 0.01 compared to respective STZ or HFF saline controls.

Figure 6. Effects of xenin-25[Lys13PAL] on pancreatic beta-cell lineage and Pdx1 expression in STZ and HFF Ins1Cre/+;Rosa26-eYFP mice. Parameters were assessed in STZ and HFF mice after 10 or 12 days, respectively, once daily treatment with saline vehicle or xenin-25[Lys13PAL] (25 nmol/kg bw). (A,B,F) Representative images (40X) of islets showing (A) insulin (red), (B) glucagon (red) and (A,B) GFP (green), or (F) insulin (red) and Pdx1 (green) immunoreactivity from each group of mice. (C) Insulin-ve/GFP+ve, (D) glucagon+ve/GFP+ve and (E) insulin+ve/Pdx1+ve islet cells. Values are mean ± SEM for 6 mice. ***p < 0.001 compared to lean controls. ∆∆p < 0.01 and ∆∆∆p < 0.001 compared to respective STZ or HFF saline controls. 
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